Heidelberg Pharma AG (LTS:0QW5) Ending Cash Position: €24.93 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QW5 Heidelberg Pharma AG LTS:0QW5
19 GF Score
Price €2.55
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG Ending Cash Position?

Heidelberg Pharma AG LTS:0QW5 -0.78% 19 Ending Cash Position is €24.93 Mil as of May. 2026. GuruFocus rates LTS:0QW5 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Heidelberg Pharma AG's Ending Cash Position for the quarter that ended in May. 2026 was €24.93 Mil.

Heidelberg Pharma AG's quarterly Ending Cash Position declined from Nov. 2025 (€14.98 Mil) to Feb. 2026 (€9.26 Mil) but then increased from Feb. 2026 (€9.26 Mil) to May. 2026 (€24.93 Mil).

Heidelberg Pharma AG's annual Ending Cash Position declined from Nov. 2023 (€43.44 Mil) to Nov. 2024 (€29.42 Mil) and declined from Nov. 2024 (€29.42 Mil) to Nov. 2025 (€14.98 Mil).

Heidelberg Pharma AG Ending Cash Position Related Terms

Heidelberg Pharma AG Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG Ending Cash Position Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.14 81.33 43.44 29.42 14.98

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.25 22.87 14.98 9.26 24.93
LTS:0QW5
19GF Score
Heidelberg Pharma AG LTS:0QW5
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Heidelberg Pharma AG's Ending Cash Position for the fiscal year that ended in Nov. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=29.421705+-14.445667
=14.98

Heidelberg Pharma AG's Ending Cash Position for the quarter that ended in May. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=9.260974+15.669515
=24.93

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €24.93 Mil mean?
Heidelberg Pharma AG (LTS:0QW5) has a Ending Cash Position of €24.93 Mil as of May. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's Ending Cash Position too high?
Heidelberg Pharma AG's current Ending Cash Position is €24.93 Mil. Overall, Heidelberg Pharma AG has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Ending Cash Position compare to VRTX and REGN?
Heidelberg Pharma AG's Ending Cash Position of €24.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current Ending Cash Position is €24.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Heidelberg Pharma AG (LTS:0QW5) has a current Ending Cash Position of €24.93 Mil. The current Ending Cash Position is €24.93 Mil. Heidelberg Pharma AG's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Heidelberg Pharma AG (LTS:0QW5), the current Ending Cash Position is €24.93 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Heidelberg Pharma AG Business Description

Other Exchanges HPHA:GermanyHPHA:Austria
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
19GF Score

Get the complete analysis for LTS:0QW5

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price